The medication Дулоксента (Duloxetine) is commonly used to help manage symptoms across multiple, often interconnected, therapeutic domains, and is considered relevant in clinical settings marked by heightened patient distress from both emotional and physical symptoms.

This medicine is considered relevant across therapeutic areas involving symptoms related to systemic imbalance and heightened neurological activity, including major depressive disorder, generalized anxiety disorder, painful diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. It helps address symptom clusters that create noticeable interference with daily stability, providing supportive relief when symptoms intensify and assisting with functional stability.

“Applied in contexts where additional symptomatic support is needed, the medicine helps manage symptoms that become more disruptive during flare-ups.”

Quick Fact: Relief for Chronic Discomfort The medication is relevant for helping with symptoms related to chronic discomfort that may be linked to nerves or chronic muscle and bone conditions, contributing to day-to-day comfort during symptomatic periods.

This section explains the official population-eligibility and non-eligibility rules for Дулоксента ( Duloxetine), as defined by governmental regulatory authorities (e.g., FDA, EMA).

Populations for Whom Use is Prohibited (Contraindicated)

The medicine is strictly contraindicated in the following groups:

• Patients with a known hypersensitivity to duloxetine or any of its components.
• Patients currently taking Monoamine Oxidase Inhibitors (MAOIs).
• Patients with uncontrolled narrow-angle glaucoma or uncontrolled hypertension.
• Patients with severe renal impairment (creatinine clearance < 30 mL/min) or liver disease resulting in hepatic impairment.

Age-Related and Conditional Eligibility

Population Group	Official Eligibility Status
Adults (ge 18 years)	Eligible for standard use.
Children/Adolescents	Not recommended for Major Depressive Disorder (MDD). Approved for specific uses (e.g., GAD ge 7 years) but carries a Boxed Warning regarding suicidal thinking/behavior risk.
Older Adults (Geriatric)	Generally eligible, but use requires caution due to regulatory-documented risks like hyponatremia and increased falls/syncope.
Pregnancy	Use only if the potential benefit justifies the potential risk to the fetus; not generally recommended.
Breastfeeding	Not recommended due to unknown safety in the nursing infant.

Official guidelines also advise caution for patients with a history of seizure disorder or mania/bipolar disorder, and for those with substantial alcohol use, who should ordinarily not be prescribed the medicine.

Interactions with other medicines and products

The interaction profile for Duloxetine (Дулоксента) is defined by documented pharmacokinetic and pharmacodynamic constraints established in official regulatory labeling.

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric treatment is formally contraindicated. A mandatory washout period of 5 to 14 days is required when switching between these agents. The drug is also contraindicated with potent CYP1A2 inhibitors, such as Fluvoxamine or Ciprofloxacin, as these agents significantly increase duloxetine exposure (plasma levels), leading to heightened pharmacokinetic risk.

Documented Pharmacodynamic Effects

The concurrent use of other serotonergic medicinal products (e.g., SSRIs, Triptans) is documented to carry a risk of Serotonin Syndrome due to additive pharmacodynamic effects. Similarly, co-administration with drugs that interfere with hemostasis (e.g., NSAIDs, oral anticoagulants) is stated to increase the risk of bleeding. Duloxetine acts as a moderate CYP2D6 inhibitor, which can increase the exposure of other co-administered medicines that are metabolized by that enzyme.

Administration and Population Constraints

Use is contraindicated in patient populations with severe renal impairment (creatinine clearance < 30 mL/min) or hepatic impairment, as these conditions heighten the risk of drug accumulation and adverse interactions. The official labeling cautions against use in patients with substantial alcohol consumption due to potential hepatotoxicity.

How Дулоксента Works

Дулоксента is a dual inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake. Its pharmacodynamic action involves blocking the neuronal reuptake transporters, specifically the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET), primarily within the central nervous system.

This blockade prevents the presynaptic neuron from clearing 5-HT and NE from the synaptic cleft, resulting in increased extracellular concentrations of both neurotransmitters. The drug works mainly through allosteric modulation of these transporter proteins. The resulting elevated neurotransmitter levels lead to the modulation of descending inhibitory pain pathways, which originate in the brainstem. This activity subsequently influences signal transduction and nociceptive processing within the spinal cord, and also affects neurotransmission in brain regions responsible for mood regulation. The drug does not exhibit significant affinity for most postsynaptic receptors, focusing its action exclusively on transporter inhibition.

How to Use Дулоксента — Administration Guidelines

Дулоксента (Duloxetine) is administered via the oral route as a hard gastro-resistant capsule. This specialized, delayed-release formulation is critical for the medicine's effectiveness, as the capsule contents must not be crushed, chewed, or opened. To maintain the integrity of the coating, the capsule must be swallowed whole and can be taken either with or without food.

---

Standard Dosing Regimens

Dosing involves specific ranges and schedules. The standard frequency is typically once daily or twice daily, depending on the specific condition being addressed.

Dosing Parameter	Standard Regimen
Starting Dose	Typically 20 mg or 30 mg once daily
Maintenance Dose	Commonly 60 mg once daily
Maximum Daily Dose	120 mg per day

Dose adjustment involves a titration principle, where the amount may be gradually escalated after one or more weeks of initial therapy. If a dose is missed, the next dose should be taken at the usual scheduled time, without taking two doses at once to compensate.

---

Procedural Constraints and Discontinuation

Specific physiological constraints govern the use of this medicine. It is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or for those with chronic liver disease or cirrhosis. When treatment is to be concluded, the protocol involves the doses being gradually reduced over a period of time before complete discontinuation (tapering). This describes the standardized approach to usage.

This overview summarizes the type of research that has been conducted on the medicine Дулоксента (Duloxetine), the outcomes these studies measured, and the areas where the evidence base remains limited, according to regulatory and scientific sources. This information is descriptive and does not constitute medical advice or clinical recommendations.

---

Evidence for Use in Mood Conditions

The clinical evaluation for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) has primarily focused on short-term, randomized controlled trials (RCTs) employing a double-blind, placebo-controlled design. Research examined the patterns of change in adult patient groups compared to those receiving an inactive substance (placebo). Outcomes related to systemic or functional imbalance were measured using standardized rating scales, along with assessments of daily functioning. For MDD, studies explored symptom patterns in adults who also reported outcomes related to physical discomfort.

Evidence for Use in Chronic Pain Conditions

The evidence base for conditions involving chronic pain, specifically for Painful Diabetic Peripheral Neuropathy (PDPN) and conditions like Fibromyalgia and certain Chronic Musculoskeletal Pain, was developed using intermediate-duration RCTs. Trials reported measurements collected for pain intensity and quality of life scores over approximately 12 to 14 weeks. The evidence forms part of the broader research landscape for these conditions, with studies describing how symptoms evolved during the defined time intervals. Findings related to measured pain outcomes were mixed and the overall evidence quality varies across the specific conditions studied.

Research Gaps and Limitations

An important point is that the follow-up durations for the primary registration studies were limited. Most core clinical trials assessed changes over short-term intervals. Consequently, long-term effects are not fully established, and there is limited information for sustained functional ability or symptom stability over many months or years. Research focusing on durability is less extensive. Additionally, the existing research primarily focuses on broad adult populations, meaning data for certain groups (such as specific comorbidity-defined groups) remain insufficient.

Common questions about Дулоксента (FAQ)

---

Q: Дулоксента – это антидепрессант или обезболивающее средство?

According to official product information, Duloxetine is classified as an antidepressant. However, regulatory documents list indications including conditions beyond depression and anxiety, such as various chronic pain conditions like Diabetic Peripheral Neuropathic Pain and Chronic Musculoskeletal Pain.

---

Q: Через какое время после начала приема обычно начинает ощущаться эффект от Дулоксенты при депрессии?

Regulatory information suggests initial improvement may be noted in some patients within 1 to 4 weeks after starting treatment. However, official guidance often notes that continued therapy for several months or longer may be necessary for the full effect to develop.

---

Q: Когда ожидать максимальный терапевтический эффект от Дулоксенты?

Clinical studies used to determine the medicine's effectiveness typically track outcomes over short-term periods, generally 8 to 12 weeks. This timeframe represents the period over which the maximum therapeutic effects are typically measured.

---

Q: Связана ли отмена Дулоксенты с синдромом отмены и как его облегчить?

Yes, abruptly stopping the medicine can lead to discontinuation symptoms, which may include dizziness, nausea, headache, and tingling sensations. Regulatory protocol requires that the dosage be gradually reduced (tapered) before stopping completely to reduce the risk of these effects.

---

Q: Как долго обычно длится курс лечения Дулоксентой?

The determination of the total duration of therapy is an individualized clinical decision. Clinical information suggests that therapy may need to be continued for several months or longer, depending on the specific condition being managed.

---

Q: Влияет ли прием пищи на время достижения максимальной концентрации Дулоксенты в крови?

Official administration instructions state that this medicine can be taken either with or without food. Taking it with food may sometimes be suggested as it may help reduce the likelihood of initial nausea.

---

Q: Существует ли риск развития зависимости или привыкания к Дулоксенте?

Regulatory documents state that the medicine has not been systematically studied for its potential for abuse or physical dependence. However, symptoms have been reported upon abrupt discontinuation, which is why tapering is required.

---

Q: Разрешено ли употребление алкоголя во время лечения Дулоксентой?

Official labeling advises against prescribing this medicine to patients who consume substantial amounts of alcohol due to an increased risk of severe liver injury (hepatotoxicity). The official label notes that alcohol consumption should be kept to a minimum.

---

Q: Можно ли применять Дулоксенту для лечения хронической боли в спине, не связанной с диабетом?

Official regulatory approvals include the management of Chronic Musculoskeletal Pain. This general indication may cover various types of chronic pain, including certain forms of chronic back pain.

---

Q: Может ли Дулоксента влиять на вес тела (вызывать набор или потерю)?

Clinical data indicates that both decreased weight (often due to decreased appetite) and weight gain have both been reported as potential adverse reactions in clinical trials for adults and children.

---

Q: Какие меры предосторожности нужно соблюдать при управлении автомобилем во время приема Дулоксенты?

The medicine is commonly associated with side effects such as dizziness and somnolence (drowsiness). Official labeling cautions that patients should use care when engaging in hazardous activities, such as driving, until they are aware of the drug’s effects on them.

---

Q: Почему Дулоксента может вызывать сухость во рту?

Dry mouth is a very common adverse reaction, documented in official product information as being reported in ge 10% of patients.

---

Q: Может ли Дулоксента вызывать тахикардию или повышение артериального давления?

Yes, the medicine is associated with increases in blood pressure (hypertension), and blood pressure should be monitored. Tachycardia (a rapid heartbeat) has also been reported in postmarketing experience.

---

Q: Почему во время приема Дулоксенты могут быть проблемы со зрением или головокружение?

Dizziness is a common side effect. Regulatory warnings indicate the medicine can cause mydriasis (pupil dilation), which is a risk factor for a specific vision problem called angle-closure glaucoma. It is therefore contraindicated in patients with uncontrolled narrow-angle glaucoma.

---

Q: Может ли Дулоксента взаимодействовать с растительными добавками, например, зверобоем?

Due to the risk of Serotonin Syndrome, official labeling warns that the medicine should be used with caution when combined with other serotonergic agents. This may include certain herbal supplements like St. John's Wort.

---

Q: Какие изменения настроения могут возникать при приеме Дулоксенты, кроме основного эффекта?

Official regulatory warnings note the potential for suicidal thoughts and behaviors, particularly during initial treatment or following dose changes. Activation of mania or hypomania has also been reported in some patients.

---

Q: Какие клинические исследования подтверждают эффективность Дулоксенты?

The medicine’s effectiveness is established by multiple short-term, randomized, double-blind, placebo-controlled trials. These studies measured changes using standardized rating scales for mood conditions and pain intensity scores.

---

Q: Влияет ли Дулоксента на аппетит?

Yes, decreased appetite is listed in the official documents as a common adverse reaction observed in clinical trials.

---

Q: Как долго действующее вещество Дулоксенты остается в организме?

According to pharmacokinetic data, the active substance has a mean elimination half-life of approximately 12 hours. This data reflects how quickly the body processes the medicine.

---

Q: Есть ли ограничения по возрасту для начала приема Дулоксенты (у взрослых)?

The medicine is approved for use in adults (ge 18 years of age). While older patients are eligible, caution is advised due to regulatory-documented risks like hyponatremia (low sodium levels) and increased risk of falls in the geriatric population.

---

Q: Могут ли появиться синяки на теле или кожная сыпь при приеме Дулоксенты?

The medicine can increase the risk of abnormal bleeding and bruising. Additionally, severe skin reactions, including rash, have been reported in the official safety profile, sometimes requiring discontinuation of the medicine.

---

Q: Какие анализы или обследования могут потребоваться перед началом лечения Дулоксентой?

Official guidelines recommend that blood pressure be measured before initiating treatment and monitored periodically thereafter. Screening for a history of bipolar disorder or mania is also recommended.

---

Q: Какие бывают симптомы передозировки Дулоксентой?

Reported symptoms following an overdose have included but are not limited to drowsiness (somnolence), seizures, vomiting, rapid heart rate, and Serotonin Syndrome.

---

Q: Может ли Дулоксента быть причиной повышенного потоотделения (гипергидроза)?

Yes, excessive sweating (hyperhidrosis) is listed in official product information as a common adverse reaction associated with the use of this medicine.

Storage Requirements

Duloxetine delayed-release capsules must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. It is mandatory to keep the product in its original container and ensure the container is tightly closed to protect the contents from moisture. The product should not be stored above 30 C or exposed to freezing temperatures. As a standard safety requirement for all prescription medication, the capsules must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired capsules must be disposed of according to local regulations or through an official drug take-back program. The official labeling advises that the product must not be disposed of via wastewater or general household trash, aligning with environmental protection guidelines for pharmaceutical waste.